Seeking Alpha

Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results

Preliminary dose-escalation data anticipated in second half of 2023 from ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-655 for patients with advanced ALK-positive NSCLC and other solid tumors ...
Seeking Alpha

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520

Publication provides comprehensive assessment of NVL-520's activity spanning preclinical characterization and preliminary clinical case studies CAMBRIDGE, Mass., Dec. 13, 2022 /PRNewswire/ -- Nuvalent ...